Patients with germline BRCA mutations who were diagnosed with breast cancer at or before age 40 and who underwent a bilateral risk-reducing mastectomy (RRM) and/or a risk-reducing ...

Olaparib, an inhibitor of poly (ADP-ribose) polymerase (PARP), has demonstrated promising outcomes in treating HER2-negative early-stage breast cancer with BRCA mutations. However, a comprehensive ...

The decision to start or add to your family is always a big one, and when you have a higher risk of cancer because of a BRCA gene mutation, it may feel even bigger. But having a BRCA1 or BRCA2 ...

her father's side is the only one with the BRCA gene. "My whole body just went like cold. I was like, 'Oh f--k.' [The doctor said], 'You need to get your ovaries out, you need to get your boobs ...

In 1989, when my grandmother passed away from cancer, our family did not have answers as to how or why. She had simply been ...

Researchers in the College of Biological Sciences are driving breakthroughs in one of the thorniest problems in science: ...

In a live virtual event, Thomas C. Krivak, MD, reviewed the key studies of PARP inhibitor and bevacizumab maintenance in ...

Bloomston emphasized the importance of awareness regarding conditions linked to pancreatic cancer, such as the BRCA mutation, ...

BOSTON — Patients with non-BRCA gene mutations undergoing risk-reduction surgery to prevent tubo-ovarian cancers showed no signs of tubo-ovarian high-grade serous carcinoma or serous tubal ...

Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window A first-line ...